PD-1

You have access
Neoadjuvant Chemoradiotherapy Enhances Tumor PD-L1 Expression in Pancreatic Cancer
KANECHIKA DEN, TAKASHI MURAKAMI, RYUSEI MATSUYAMA, KENTARO MIYAKE, YUKI HOMMA, YASUHIRO YABUSHITA, RYUTARO MORI, YUKIHIKO HIROSHIMA, IKUMA KATO and ITARU ENDO

Anticancer Research April 2025, 45 (4) 1731-1747; DOI: https://doi.org/10.21873/anticanres.17554
Open Access
Peripheral CD4⁺ T Cells Predict T Cell Immunity in Lung Tissues of Non-small Cell Lung Cancer Patients
MARI TONE, TOMOMI ISONO, YOKO YAMAMOTO, YOSHITO TAKEDA, YASUSHI SHINTANI, ATSUSHI KUMANOGOH, HISASHI WADA and KOTA IWAHORI

Anticancer Research March 2025, 45 (3) 909-920; DOI: https://doi.org/10.21873/anticanres.17478
You have access
Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma
YOUNG WHA KOH, JAE-HO HAN, SEOKJIN HAAM and HYUN WOO LEE

Anticancer Research May 2024, 44 (5) 2081-2089; DOI: https://doi.org/10.21873/anticanres.17012
Open Access
Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab
NAOTO WAKITA, NOBUYUKI HINATA, YUKARI BANDO, TAKUTO HARA, TOMOAKI TERAKAWA, JUNYA FURUKAWA, YUZO NAKANO and MASATO FUJISAWA

Anticancer Research February 2023, 43 (2) 841-847; DOI: https://doi.org/10.21873/anticanres.16226
You have access
Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis
CHIERI NAKAYAMA, KIYONORI TANOUE, TETSUYA IDICHI, HIROKI SHIMOMURA, YOSHIAKI KITA, YUTO HOZAKA, YOSHIAKI SHINDEN, DAISUKE MATSUSHITA, AKIHIRO NAKAJO, TAKAAKI ARIGAMI, YUKO MATAKI, HIROSHI KURAHARA and TAKAO OHTSUKA

Anticancer Research July 2022, 42 (7) 3373-3380; DOI: https://doi.org/10.21873/anticanres.15824
Open Access
Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer
THOMAS HECKING, THORE THIESLER, JANINA HALBE, LUCIA OTTEN, FLORIAN RECKER, HEIDRUN GEVENSLEBEN, TIM MÜLLER, CYNTHIA SCHILLER, EVA K. EGGER, ROLF FIMMERS, MATTHIAS B. STOPE, GLEN KRISTIANSEN and ALEXANDER MUSTEA

Anticancer Research March 2022, 42 (3) 1367-1376; DOI: https://doi.org/10.21873/anticanres.15606
You have access
The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment
PRAJWAL NEUPANE, KOSAKU MIMURA, SHOTARO NAKAJIMA, HIROKAZU OKAYAMA, MISATO ITO, AUNG KYI THAR MIN, KATSUHARU SAITO, HISASHI ONOZAWA, SHOTARO FUJITA, WATARU SAKAMOTO, MOTONOBU SAITO, ZENICHIRO SAZE, TOMOYUKI MOMMA and KOJI KONO

Anticancer Research October 2021, 41 (10) 4895-4905; DOI: https://doi.org/10.21873/anticanres.15303
You have access
Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer
KUNIHIKO KOBAYASHI, KYOICHI KAIRA and HIROSHI KAGAMU

Anticancer Research September 2020, 40 (9) 5309-5311; DOI: https://doi.org/10.21873/anticanres.14537
You have access
Mutant KRAS Promotes NKG2D⁺ T Cell Infiltration and CD155 Dependent Immune Evasion
KENSUKE NISHI, SHUHEI ISHIKURA, MASAYO UMEBAYASHI, TAKASHI MORISAKI, TAKASHI INOZUME, TETSUSHI KINUGASA, MIKIKO AOKI, SATOSHI NIMURA, ANTHONY SWAIN, YOICHIRO YOSHIDA, SUGURU HASEGAWA, KAZUKI NABESHIMA, TOSHIFUMI SAKATA, SENJI SHIRASAWA and TOSHIYUKI TSUNODA

Anticancer Research August 2020, 40 (8) 4663-4674; DOI: https://doi.org/10.21873/anticanres.14465
You have access
Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer
HAYATO KAWACHI, DAICHI FUJIMOTO, DAISUKE YAMASHITA, JUNYA FUKUOKA, YUKA KITAMURA, KAZUTAKA HOSOYA, YUKI SATO, KAZUMA NAGATA, ATSUSHI NAKAGAWA, RYO TACHIKAWA, NAOKI DATE, ICHIRO SAKANOUE, HIROSHI HAMAKAWA, YUTAKA TAKAHASHI and KEISUKE TOMII

Anticancer Research May 2019, 39 (5) 2561-2567; DOI: https://doi.org/10.21873/anticanres.13378

Main menu

User menu

Search

PD-1

Pages